Introduction {#S8}
============

Severe acute respiratory syndrome virus (SARS-CoV-2) has infected millions of people worldwide \[[@R1]\]. Despite the global impact, key gaps in knowledge persist. A comprehensive assessment of patients evaluated for SARS-CoV-2, from testing to outcome, is needed to guide public health recommendations and scientific investigations into the mechanisms of disease pathogenesis.

Prior studies have identified many risk factors for SARS-CoV-2 infections and complications \[[@R2]--[@R5]\]. Older age and male sex have been consistently associated with worse outcomes, as have many chronic cardiovascular and respiratory diseases \[[@R3]--[@R6]\]. Despite some consistent themes, reports from different geographic locations have reported variation in both risks and mortality rates \[[@R7]--[@R11]\]. No study yet exists that describes the characteristics and outcomes of a single cohort from testing to outcome and with detailed information on treatments in a racially and ethnically diverse population.

Drawing from a highly curated real-world data set, we describe a diverse cohort from a catchment area that represents the diversity of the nation located in an early epicenter of the US outbreak. We extend the current literature with a detailed assessment of the characteristics of patients tested, and the clinical courses and outcomes of those testing positive, and among those admitted with SARS-CoV-2. We sought to identify risk factors for admission among those with SARS-CoV-2 and in-hospital mortality among discharged patients. We also characterize the patterns of treatment to provide the context to guide interpretation of these results.

Methods {#S9}
=======

Study Setting and Data Collection: {#S10}
----------------------------------

This was an observational, retrospective study of patients who were tested for SARS-CoV-2 within the Yale New Haven Health (YNHH) system, located within one of the US epicenters of Covid-19. The healthcare system is comprised of a mix of pediatric, suburban community, urban community, and urban academic inpatient facilities at five sites with a total of 2,681 licensed beds and 124,668 inpatient discharges in 2018 \[[@R12]\]. The system also includes associated outpatient facilities that had 2.4 million outpatient encounters in 2018. YNHH uses a single electronic health record (EHR) across the health system. Patient demographics, past medical histories, medications, and clinical outcomes were extracted from our local Observational Medical Outcomes Partnership (OMOP) \[[@R13]\] data repository and analyzed within our computational health platform \[[@R14],[@R15]\]. Data were extracted with custom PySpark (version 2.4.5) scripts that were reviewed by an independent analyst. The study was approved by the Yale University Institutional Review Board (protocol \#2000027747).

Study Cohort: {#S11}
-------------

The study cohort consists of all adult patients (≥18 years old) at YNHH who had an order for SARS-CoV-2 RT-PCR testing and a test result documented within the medical record between March 1, 2020 and April 30, 2020 ([Supplemental Figure 1](#SD1){ref-type="supplementary-material"}). SARS-CoV-2 testing in our health system was limited to symptomatic patients for whom the provider had a concern for respiratory tract infection in the month of March. Testing increased to include a wider breadth of symptoms deemed clinically concerning during the month of April. By the end of April, all patients admitted to the health system were tested for Covid-19. Outpatient testing required a physician order and was primarily sent to external reference laboratories. The decision to test was ultimately left to the ordering provider. Testing was first made available to order within the health system on March 13th, 2020.

Patients admitted more than 24 hours prior to testing were excluded from the admissions group to reduce the likelihood of including hospital acquired infections. Data and outcomes were limited to those collected between March 1, 2020 and April 30, 2020. An extract of our local OMOP data repository from May 4, 2020 was used to allow for final discharge disposition and vendor-provided transformations of the clinical data warehouse to complete. For patients with multiple admissions in the study period, only data from the first admission was used. Race and ethnicity were extracted from the demographics section of the EHR and mapped to the OMOP common data model ([Supplemental Table 1](#SD1){ref-type="supplementary-material"}). For demographic fields that had selected values or responses, individual counts were further anonymized to remove any counts ≤3.

Outcome Ascertainment: {#S12}
----------------------

We extracted primary outcomes of admission and discharge disposition along with secondary outcomes of supplemental oxygen use and mechanical respiratory support. The maximum respiratory requirement during admission was used. Covid-19 related admissions were identified by extracting data from each patient's first inpatient admission that had a visit start time within a window 14 days following or 24 hours before a positive SARS-CoV-2 test was ordered for a patient. Visit-related data and in-hospital mortality were directly extracted from our OMOP data repository. Supplemental oxygen requirements were computed based on presence of clinical documentation in flowsheets or vitals measurements and were mapped to one of four categorical variables: low-flow oxygen, high-flow oxygen, noninvasive mechanical ventilation, and/or invasive mechanical ventilation. Outcomes were limited to patients who were discharged and were therefore not extracted for patients who were still admitted at the end of the study period. Digitally extracted outcomes were validated for 30 patients via medical record review by a clinician. All ages were calculated relative to the time of SARS-CoV-2 test order.

Treatment Pathways: {#S13}
-------------------

To document clinical treatment pathways, we extracted medication administration records of all admitted patients for their initial visit. Medications related to Covid-19 treatment based on institutional guidelines were grouped by calendar day of first administration. All forms of corticosteroids were mapped to a single drug class rather than their individual active ingredients. The order of medication initiation defined the separate treatment regimens and final treatment pathway. Treatment pathway visualizations were created with the JavaScript library Data Driven Documents (D3, version 4) \[[@R16]\].

Statistical Analyses: {#S14}
---------------------

The tables of demographic data and outcome data were built using the R (version 3.5.1) package tableone. Logistic regressions were performed using the core R function glm. Model 1 was among those testing positive to identify risk factors associated with admission. Candidate variables included the features described in [Table 1](#T1){ref-type="table"}. Before computing the final model, the variables for "Other" race and ethnicity of "Not Hispanic" were removed in order to ensure that all variables in the model had variance inflation factor less than 3. Model 2 was among those with a final discharge disposition at the end of the study period (right-censored for patients who were still admitted) to identify risk factors associated with in-hospital mortality. We began with the variables used in the admission model, and removed the race variables for "American Indian or Alaska Native" and "Native Hawaiian or Other Pacific Islander", and the age variable "Age 35--44". This was done to ensure the variation inflation factors would all be less than 10. A value of p\<0.05 was used as the threshold for significance without adjustment for multiple comparisons.

Elixhauser comorbidity \[[@R17]\] analysis was performed using the R comorbidity package (version 0.5.3) \[[@R18]\]. Briefly, ICD-10 codes from each patient's medical history taken from the OMOP database were used to generate presence or absence of the 31 Elixhauser comorbidity categories, as well as weighted scores using the AHRQ and van Walraven algorithms \[[@R19],[@R20]\].

Age-adjusted in-hospital mortality was calculated with direct standardization \[[@R21]\] based on the discharge population. In this method, age-specific rates are weighted according to the prevalence of age groups within an a priori standard population. This converts the observed age-specific rates of some process into a rate which would be observed had that same process acted upon the standard population. The 2000 US population was used as the standard population for age adjustment \[[@R21]\]. We used weights for five-year age groupings from ages 15 to 84 and a final group of 85 and over.

Results {#S15}
=======

The number of patients positive for SARS-CoV-2 increased rapidly beginning in March 2020 ([Supplemental Figure 2](#SD1){ref-type="supplementary-material"}). A total of 28605 patients were tested for SARS-CoV-2 with 7995 patients (27.9%) who had at least one positive result during the observation period. Of those with positive tests, 2154 (26.9%) had an associated hospital admission. Of admitted patients, 1633 (75.8%) had a final discharge disposition and 521 (24.2%) remained hospitalized at the end of the study period. For SARS-CoV-2 infected patients who were not admitted, the median number of days elapsed between testing and the study end date was 23.4 days (IQR 14.6--30.6).

Characteristics of Individuals Tested for SARS-CoV-2: {#S16}
-----------------------------------------------------

Of the patients tested for SARS-CoV-2, a majority (n=17191; 60.1%) were female ([Table 1](#T1){ref-type="table"}). The most common comorbidities were uncomplicated hypertension (n=11950; 41.8%), chronic pulmonary disease (n=9043; 31.6%), and depression (n=7697; 26.9%). The median age of tested adults was 50.8 years (IQR 36.1--63.5). In those tested for SARS-CoV-2, 4.8% did not have a reported race within the demographics section of the EHR. The majority of tested patients were reported as White (n=16825; 58.8%), followed by Black (n=5093; 17.8%) and Other race (n=4464; 15.6%). Those who self-identified as Hispanic ethnicity represented 19.1% (n=5468) of the tested population. Testing frequency by race and ethnicity showed slight overrepresentation of minority groups based on the census numbers for Connecticut, which has a demographic breakdown of 66.9% White, 12.2% Black, 5.0% Asian, 0.6% American Indian or Alaskan Native, 0.1% Native Hawaiian or Pacific Islander, and 16.9% Hispanic \[[@R22]\].

Age was similarly distributed between the SARS-CoV-2 tested and positive populations. Of those who tested positive, the median age was 52.3 years (IQR 38.3--64.8). Patients with a positive test were more frequently female (n=4435, 55.5%) with uncomplicated hypertension (n=3334, 41.7%), obesity (n=2195, 27.5%), and chronic pulmonary disease (n=2005, 25.1%) as the most common comorbidities. Patients with a positive test were most frequently reported as White (n=3616, 45.2%), followed by Other race (n=1874, 23.4%) and Black (n=1856, 23.2%). Those who were reported as Hispanic ethnicity accounted for 28.1% (n=2245) of SARS-CoV-2 positive patients.

Features Associated with Admission in Patients with Covid-19: {#S17}
-------------------------------------------------------------

The median age of SARS-CoV-2 positive patients admitted to the hospital was 66.2 years (IQR 53.7--79.9) and a majority were male (n=1119, 52.1%) as shown in [Table 1](#T1){ref-type="table"}. The most common Elixhauser comorbidities for admitted patients included uncomplicated hypertension (n=1387, 64.4%), fluid & electrolyte disorders (n=905, 42.0%), and diabetes without complications (n=810, 37.6%). Minority groups were overrepresented in the admitted population compared to census numbers, particularly for those with a recorded race of Black (n=546, 25.3%) or Other race (n=497, 23.1%). Those recorded as Hispanic ethnicity accounted for 26.0% (n=560) of admitted patients.

In multivariable analyses, older age was significantly associated with risk of admission ([Figure 1](#F1){ref-type="fig"}, [Supplemental Table 2](#SD1){ref-type="supplementary-material"}). Age ≥85 years had the highest risk of admission (OR 22.03, 95%CI=16.10--30.30). Male sex was also associated with increased risk of admission (OR 1.68, 95%CI=1.45--1.90). The comorbidities associated with increased risk of admission included fluid & electrolyte disorders (OR 1.99, 95%CI=1.67--2.37), psychoses (OR 1.98, 95%CI=1.47--2.69), metastatic cancer (OR 1.55, 95%CI=1.11--2.15), pulmonary circulation disorders (OR 1.53, 95%CI=1.14--2.06), peptic ulcer disease (OR 1.47, 95%CI=1.04--2.07), drug abuse (OR 1.46, 95%CI=1.11--1.92), renal failure (OR 1.38, 95%CI=1.08--1.75), and obesity (OR 1.18, 95%CI=1.02--1.37). Of note, complicated hypertension (OR 1.14, 95%CI=0.88--1.48), uncomplicated hypertension (OR 0.97, 95%CI=0.83--1.13), and chronic pulmonary disease (OR 0.94, 95%CI=0.81--1.09) were not found to significantly increase the risk of admission. Recorded races with increased risk of admission included Asian (OR 1.58, 95%CI=1.02--2.41) and Black (OR 1.43, 95%CI=1.14--1.78). Hispanic ethnicity was also associated with increased risk of admission (OR 1.81, 95%CI=1.50--2.18).

Outcomes in Discharged Patients with Covid-19: {#S18}
----------------------------------------------

Of the patients admitted for COVID-19 the majority (n=1633, 75.8%) were discharged and therefore had complete outcomes available at the end of the study period ([Table 2](#T2){ref-type="table"}). The median length of stay for discharged patients was 6.7 days (IQR 3.7--11.1) and the median length of stay for patients still admitted to the hospital at the end of the study period was 8.4 days (IQR 3.2--17.3). Mortality occurred in the emergency department for 8 of these patients who were excluded from respiratory analysis as they did not have complete respiratory outcomes reported.

The majority of patients with respiratory outcomes required a maximum of non-invasive respiratory support (n=1433, 88.2%). Of these patients, male and female sex was similar in frequency (male=714, 49.8%) with most frequently self-reported races of White (n=683, 47.7%), Black (n=358, 25.0%), and Other race (n=327, 22.9%). The most prevalent comorbidities included uncomplicated hypertension (n=906, 63.2%), fluid & electrolyte disorders (n=569, 39.7%), and cardiac arrhythmia (n=523, 36.5%). Invasive ventilatory support was required for 11.8% (n=192) of patients with respiratory outcomes. The majority of those who required invasive ventilatory support were male (n=127, 66.1%) with self-reported race of White (n=79, 41.1%), Black (n=52, 27.1%), and Other race (n=52, 27.1%). The most prevalent comorbidities included uncomplicated hypertension (n=121, 63.0%), fluid & electrolyte disorders (n=80, 41.7%), and diabetes without complication (n=80, 41.7%).

In-hospital mortality was 13.9% (n=227) of patients with a discharge disposition and these patients had a median length of stay of 5.8 days (IQR 2.7--11.1). The majority of patients who experienced in-hospital mortality were male (n=127, 55.9%) and mortality increased with age ([Figure 2A](#F2){ref-type="fig"}); the median age of those who experienced in-hospital mortality was 81.9 (IQR 72.6--89.0) years. Those with older age, particularly those ≥85 years old, predominantly self-reported a race of White ([Figure 2B](#F2){ref-type="fig"}). The comorbidities most common among those who expired were uncomplicated hypertension (n=192, 84.6%), fluid & electrolyte disorders (n=142, 62.6%), and cardiac arrhythmia (n=126, 55.5%). Those who were admitted and/or experienced in-hospital mortality compared to those who tested positive for SARS-CoV-2 in all racial and ethnic groups had an increased comorbidity burden as determined by weighted Elixhauser comorbidity scores ([Figure 2C](#F2){ref-type="fig"}, [2D](#F2){ref-type="fig"}), with the exception of those with Unknown ethnicity which represented a small number of patients (n=4). For those who expired, the most common recorded races were White (n=149, 65.6%), Black (n=48, 21.1%), and Other race (n=24, 10.6%). Those who reported Hispanic ethnicity accounted for 12.8% (n=29) of in-hospital mortality. In-hospital, age-adjusted mortality rates were 4.3%, 3.3%, 4.6%, 4.0%, and 3.1% for those who reported a race of White, Black, Asian, Hawaiian or Pacific Islander, and Other race, respectively ([Supplemental Figure 3](#SD1){ref-type="supplementary-material"}). Those who reported Hispanic ethnicity had an age-adjusted in-hospital mortality rate of 3.4%.

As seen with admission, regression analysis demonstrated that increased age had the highest risk for in-hospital mortality ([Figure 3](#F3){ref-type="fig"}, [Supplemental Table 3](#SD1){ref-type="supplementary-material"}), with the largest risk seen for those ≥85 years old (OR 22.9, 95%CI=9.0--71.2). Male sex was also associated with increased risk of in-hospital mortality (OR 1.87, 95%CI=1.33--2.63). Of the comorbidities present within the medical history and problem list of the EHR, only a history of blood loss anemia was significant (OR 1.81, 95%CI=1.03--3.12). Race was not statistically associated with a risk of in-hospital mortality in this cohort.

Treatment Pathways for Admitted Patients with Covid-19: {#S19}
-------------------------------------------------------

Of patients with known outcomes, 1412 (86.5%) received medications for Covid-19 treatment while admitted. We assessed treatment pathways for 13 Covid-19 related medications. Patients were treated with 162 different possible medication regimen permutations with 50 unique combinations ([Figure 4](#F4){ref-type="fig"}, [Supplemental Table 4](#SD1){ref-type="supplementary-material"}). The most common first line regimens included hydroxychloroquine (95.8% of patients), tocilizumab (46.2%) and azithromycin (32.7%). The most frequent second-line regimens, aside from the most frequent first line agents, included the addition of steroids (19.3%), atazanavir (19.3%), and lopinavir/ritonavir (8.9%). The most common treatment permutations were hydroxychloroquine alone (25.4%), hydroxychloroquine in combination with tocilizumab (17.6%), or hydroxychloroquine in combination with azithromycin (10.1%). A total of just six Covid-19 related medications were given to more than 1% of admitted patients in our cohort: hydroxychloroquine sulfate (95.8%), tocilizumab (46.2%), azithromycin (32.7%), atazanavir (19.3%), steroids (19.3%) and lopinavir/ritonavir (8.9%). All race and ethnicity groups were prescribed hydroxychloroquine most frequently, with patients who self-reported as Asian having the lowest rate (90.6%). Tocilizumab was the second most frequently prescribed medication in all groups except those who identified as Other race or who did not identify with a specific group. The use of azithromycin had the most notable variation among groups: it was the second most common medication in those identifying as Other race, with a frequency of 50.0% of patients, but was fifth most common among those who identified as Black, with only 17.6% of patients receiving azithromycin.

Discussion {#S20}
==========

In one of the largest real-world analyses of risk factors associated with Covid-19 infection and disease severity, we identified age as the primary risk factor associated with both admission and in-hospital mortality in those infected with SARS-CoV-2. Black race and Hispanic ethnicity were associated with increased risk of admission in our cohort and had increased disease and mortality burden, but age-adjusted in-hospital mortality was similar among all reported races and ethnicities. Comorbidities had much less impact on risk for either admission or in-hospital mortality in our study.

Our work extends the literature in several important ways. Firstly, we followed a single large cohort to identify risks associated with infection and severe disease from the time of testing through discharge. Secondly, we provide further evidence that age and male sex are significantly associated risk factors for both admission and in-hospital mortality. Thirdly, we found that comorbidities, while common in those with SARS-CoV-2, were not strongly associated with either admission or in-hospital mortality based on multivariable analysis. Fourthly, we found race and ethnicity to be associated with infection and admission in this cohort, but with in-hospital mortality that was similar among these groups in our discharged population. Finally, we identified consistent use of medications within our admitted population, but with many possible treatment pathways for any individual patient and with frequent use of investigational therapies for Covid-19.

Our data confirm findings in other studies that show age as a primary risk factor for admission and in-hospital mortality in adult patients and that male sex is also highly associated with these outcomes \[[@R5],[@R7],[@R23]--[@R25]\]. While the mechanisms that may lead to more severe disease in men have not been definitively elucidated, several potential mechanisms have been proposed to explain the demonstrated differences, including increased comorbidities and changes in the immune response in those who are male and older, along with possible genetic/biologic differences that may increase disease severity in men \[[@R26]\]. Similarly, immune senescence, with dysregulated inflammation and decreased adaptive immune response, has been hypothesized as a possible reason for worse disease in older populations \[[@R27]\].

Many studies have shown that Covid-19 has disproportionately affected minority populations across the US \[[@R28]--[@R31]\]. Within our cohort, Black and Hispanic populations were overrepresented in those who were tested, positive, and admitted for SARS-CoV-2 compared to census data for Connecticut. Studies based on regional mortality data, which have included out-of-hospital mortality, have shown that severe disease may also be more prevalent in minority populations \[[@R10],[@R29]\]. In our study, Black race was overrepresented in those with more severe outcomes compared to state census numbers. However, in the discharged population, we found that age-adjusted, in-hospital mortality was similar among all racial and ethnic groups, with rates ranging from 3.1% to 4.6%. This finding is consistent with other studies of in-hospital mortality related to Covid-19 \[[@R3],[@R23]\], but also demonstrates that minority populations experience a higher overall burden of disease. While a small percentage of this cohort did not have race or ethnicity data provided, it remains limited by the potential for errors during patient registration and the possibility of provider-reported responses.

Our data reflect the prominence of comorbidities in those with SARS-CoV-2 infection. While comorbidities were common, some of the most commonly reported risks for severe disease \[[@R2],[@R32],[@R33]\] were not identified as risks in this study and multivariable analysis did not find a history of hypertension or diabetes to be significantly associated with admission. An increased comorbidity burden was noted in those with in-hospital mortality compared to those who were discharged alive. However, multivariable analysis only identified a history of blood loss anemia to be significantly associated with in-hospital mortality. Other comorbidities, such as obesity, were associated with admission but not in-hospital mortality. It is unclear if these patients required admission due to more severe disease or were admitted due to perceived risk based on early reports of Covid-19 risk factors. Similarly, a history of drug abuse and psychoses were associated with admission, but likely represented more frequent testing in these populations with limited ability to discharge patients to shared facilities following a positive SARS-CoV-2 test. These findings highlight the fact that age and sex appear to be the predominant drivers of severe disease. Additional studies will be needed to further characterize the risk of underlying disease on the severity of Covid-19.

The risks and outcomes reported here should be assessed in the context of the treatment protocols used during this period of the epidemic. Treatment standards based on early recommendations led to a majority of patients receiving disease related therapy, often with investigational treatments. Greater than 95% of those patients who received a Covid-19 targeted therapy received hydroxychloroquine, 46% received tocilizumab, and 33% received azithromycin. The use of Covid-19 directed treatments was consistent among races and ethnicities in our cohort. But despite an early push to use promising medications from in vitro studies, such as hydroxychloroquine and azithromycin, evidence now demonstrates that neither is likely beneficial for admitted patients. As such, the treatment context of future studies should be similarly assessed to determine whether changes in treatment pathways impact the reported risks and outcomes in those with Covid-19.

Our analysis leveraged real-world data derived from the EHR to assess all patients tested for SARS-CoV-2 within our health system. We implemented computed phenotypes to identify cases and clinically relevant outcomes, with a subset manually reviewed for accuracy. Our findings add to a growing base of evidence related to Covid-19 risk factors and outcomes. However, as an observational study based on real-world data, this study also has several limitations. First, while standardized testing protocols were in place, testing was often limited to symptomatic individuals or those with known exposure risks, thus potentially biasing our cohort to those who were symptomatic and sought care. The study was also limited to a single health system, but one that consists of a mixture of academic, urban, and suburban care facilities with a diverse patient population. In addition, while our health system implemented standardized treatment protocols, patients received therapies that were investigational for Covid-19 at the time of the study, and use of these medications may not be similar at all institutions, especially as Covid-19 treatment protocols rapidly evolve as new evidence is obtained. Another limitation is that features associated with risk of admission may not correlate to risk of disease severity, as the decision to admit can be impacted based on discharge options or perceived clinical risks by healthcare providers. Finally, due to the timeline of the current outbreak, this study was limited to the initial admission and only assessed in-hospital mortality in a discharged population over a short follow-up period. Therefore, additional studies are needed to assess the impact of disease on patients not admitted to the hospital and the long-term effects of SARS-CoV-2 infection.

There is an ongoing need to rapidly generate and communicate evidence, while also being cautious that only high-quality data are used to inform policy and develop clinical recommendations. While waiting for larger, more comprehensive case control and population-scale studies to define COVID-19 specific risks, prevalence, treatment, and outcomes, providers and public health officials need the best available evidence for clinical use. The data presented here provide findings from a large cohort that was followed from testing through discharge, identified increased age and male sex as the strongest risk factors for admission and in-hospital mortality, and found that in-hospital mortality was similar in racial and ethnic groups within our health system. Ongoing studies that further elucidate the risk of comorbidities, particularly given rapidly evolving treatment guidelines, remain needed as the Covid-19 pandemic continues to grow.

Conclusion {#S21}
==========

The early COVID-19 experience at YNHH demonstrated that increasing age and male sex are the risks most strongly associated with admission and in-hospital mortality in those with SARS-CoV-2 infection. Minority racial and ethnic groups had increased risk of admission and higher disease burden, including mortality. But, for discharged patients, in-hospital mortality rates were similar in all racial and ethnic groups. While comorbidities were frequently observed in patients with SARS-CoV-2, few were associated with admission or in-hospital mortality in our cohort. Despite the limitations, this dataset from a multi-hospital health system with a diverse patient population presents valuable information related to risk factors for SARS-CoV-2 infection and short-term outcomes.
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###### 

Demographics and Elixhauser comorbidities of all patients tested, tested positive, and admitted for SARS-CoV-2.

                                                     Tested         Positive      Admitted
  -------------------------------------------------- -------------- ------------- --------------
  Sex (%)                                                                         
   FEMALE                                            17191 (60.1)   4435 (55.5)   1031 (47.9)
   MALE                                              11404 (39.9)   3558 (44.5)   1123 (52.1)
   UNKNOWN                                           10 (0.0)       2 (0.0)       0 (0.0)
  Race (%)                                                                        
   American Indian                                   60 (0.2)       12 (0.2)      \<10 (\<0.5)
   Asian                                             721 (2.5)      175 (2.2)     44 (2.0)
   Black                                             5093 (17.8)    1856 (23.2)   546 (25.3)
   Hawaiian/Pacific Islander                         79 (0.3)       30 (0.4)      \<10 (\<0.5)
   Other                                             4464 (15.6)    1874 (23.4)   497 (23.1)
   Unknown/Not Stated                                1363 (4.8)     432 (5.4)     37 (1.7)
   White                                             16825 (58.8)   3616 (45.2)   1021 (47.4)
  Ethnicity (%)                                                                   
   Hispanic or Latino                                5468 (19.1)    2245 (28.1)   560 (26.0)
   Not Hispanic or Latino                            21540 (75.3)   5265 (65.9)   1559 (72.4)
   Unknown/Not Stated                                1597 (5.6)     485 (6.1)     35 (1.6)
  Age (%)                                                                         
   18--34                                            6581 (23.0)    1579 (19.7)   146 (6.8)
   35--44                                            4880 (17.1)    1321 (16.5)   181 (8.4)
   45--54                                            5207 (18.2)    1546 (19.3)   258 (12.0)
   55--64                                            5480 (19.2)    1583 (19.8)   435 (20.2)
   65--74                                            3194 (11.2)    885 (11.1)    402 (18.7)
   75--84                                            1928 (6.7)     565 (7.1)     374 (17.4)
   85+                                               1335 (4.7)     516 (6.5)     358 (16.6)
  Elixhauser Comorbidities (%)                                                    
   AIDS/HIV                                          248 (0.9)      75 (0.9)      32 (1.5)
   Alcohol abuse                                     2141 (7.5)     398 (5.0)     175 (8.1)
   Blood loss anemia                                 1228 (4.3)     305 (3.8)     144 (6.7)
   Cardiac arrhythmias                               7242 (25.3)    1691 (21.2)   803 (37.3)
   Chronic pulmonary disease                         9043 (31.6)    2005 (25.1)   717 (33.3)
   Coagulopathy                                      2450 (8.6)     511 (6.4)     265 (12.3)
   Congestive heart failure                          3155 (11.0)    805 (10.1)    494 (22.9)
   Deficiency anemia                                 3787 (13.2)    978 (12.2)    409 (19.0)
   Depression                                        7697 (26.9)    1664 (20.8)   637 (29.6)
   Diabetes, complicated                             3817 (13.3)    1190 (14.9)   624 (29.0)
   Diabetes, uncomplicated                           5502 (19.2)    1738 (21.7)   810 (37.6)
   Drug abuse                                        2548 (8.9)     401 (5.0)     173 (8.0)
   Fluid and electrolyte disorders                   6540 (22.9)    1623 (20.3)   905 (42.0)
   Hypertension, complicated                         3666 (12.8)    988 (12.4)    616 (28.6)
   Hypertension, uncomplicated                       11950 (41.8)   3334 (41.7)   1387 (64.4)
   Hypothyroidism                                    4467 (15.6)    1154 (14.4)   448 (20.8)
   Liver disease                                     3417 (11.9)    755 (9.4)     283 (13.1)
   Lymphoma                                          421 (1.5)      71 (0.9)      29 (1.3)
   Metastatic cancer                                 1557 (5.4)     271 (3.4)     140 (6.5)
   Obesity                                           7654 (26.8)    2195 (27.5)   684 (31.8)
   Other neurological disorders                      3481 (12.2)    939 (11.7)    542 (25.2)
   Paralysis                                         672 (2.3)      203 (2.5)     118 (5.5)
   Peptic ulcer disease, excluding bleeding          989 (3.5)      217 (2.7)     113 (5.2)
   Peripheral vascular disorders                     3416 (11.9)    875 (10.9)    523 (24.3)
   Psychoses                                         1259 (4.4)     330 (4.1)     206 (9.6)
   Pulmonary circulation disorders                   1568 (5.5)     358 (4.5)     226 (10.5)
   Renal failure                                     2888 (10.1)    809 (10.1)    515 (23.9)
   Rheumatoid arthritis/collagen vascular diseases   2145 (7.5)     432 (5.4)     174 (8.1)
   Solid tumor without metastasis                    3023 (10.6)    658 (8.2)     313 (14.5)
   Valvular disease                                  4188 (14.6)    1011 (12.6)   528 (24.5)
   Weight loss                                       2864 (10.0)    664 (8.3)     357 (16.6)

###### 

Discharge and respiratory outcomes (highest requirement during admission) for all patients with known disposition categorized by sex, race, ethnicity and Elixhauser comorbidities. Expired includes those that expired in the ED without known respiratory outcomes.

                                                     Discharged    No Oxygen      Low Flow       High Flow     Noninvasive    Invasive      Discharged Alive   Expired
  -------------------------------------------------- ------------- -------------- -------------- ------------- -------------- ------------- ------------------ -------------
  Sex                                                                                                                                                          
   MALE (%)                                          845 (51.7)    163 (44.9)     312 (48.4)     223 (56.9)    16 (47.1)      127 (66.1)    718 (51.1)         127 (55.9)
  Race (%)                                                                                                                                                     
   Asian                                             37 (2.3)      \<10 (\<2.8)   \<15 (\<2.3)   10 (2.6)      \<6 (\<17.8)   \<5 (\<2.6)   33 (2.3)           \<5 (\<2.2)
   Black/African-American                            411 (25.2)    97 (26.7)      174 (27.0)     81 (20.7)     \<6 (\<17.8)   52 (27.1)     363 (25.8)         48 (21.1)
   Hawaiian/Pacific Islander                         6 (0.4)       \<10 (\<2.8)   \<15 (\<2.3)   \<4 (\<1.0)   \<6 (\<17.8)   \<5 (\<2.6)   4 (0.3)            \<5 (\<2.2)
   Other                                             382 (23.4)    93 (25.6)      137 (21.3)     89 (22.7)     8 (23.5)       52 (27.1)     358 (25.5)         24 (10.6)
   Unknown/Not Stated                                31 (1.9)      \<10 (\<2.8)   19 (3.0)       \<4 (\<1.0)   \<6 (\<17.8)   \<5 (\<2.6)   31 (2.2)           \<5 (\<2.2)
   White                                             766 (46.9)    158 (43.5)     299 (46.4)     208 (53.1)    18 (52.9)      79 (41.1)     617 (43.9)         149 (65.6)
  Ethnicity (%)                                                                                                                                                
   Hispanic or Latino                                438 (26.8)    109 (30.0)     166 (25.8)     91 (23.2)     9 (26.5)       60 (31.2)     409 (29.1)         29 (12.8)
   Not Hispanic or Latino                            1169 (71.6)   251 (69.1)     462 (71.7)     298 (76.0)    25 (73.5)      128 (66.7)    975 (69.3)         194 (85.5)
   Unknown/Not Stated                                26 (1.6)      3 (0.8)        16 (2.5)       3 (0.8)       0 (0)          4 (2.1)       22 (1.6)           4 (1.8)
  Age (%)                                                                                                                                                      
   18--34                                            125 (7.7)     67 (18.5)      31 (4.8)       15 (3.8)      \<4 (\<11.8)   11 (5.7)      124 (8.8)          \<5 (\<2.2)
   35--44                                            160 (9.8)     56 (15.4)      53 (8.2)       27 (6.9)      \<4 (\<11.8)   21 (10.9)     156 (11.1)         \<5 (\<2.2)
   45--54                                            200 (12.2)    48 (13.2)      86 (13.4)      40 (10.2)     \<4 (\<11.8)   22 (11.5)     196 (13.9)         \<5 (\<2.2)
   55--64                                            322 (19.7)    62 (17.1)      140 (21.7)     69 (17.6)     5 (14.7)       45 (23.4)     299 (21.3)         23 (10.1)
   65--74                                            293 (17.9)    44 (12.1)      135 (21.0)     65 (16.6)     9 (26.5)       40 (20.8)     256 (18.2)         37 (16.3)
   75--84                                            286 (17.5)    45 (12.4)      111 (17.2)     79 (20.2)     8 (23.5)       39 (20.3)     211 (15.0)         75 (33.0)
   85+                                               247 (15.1)    41 (11.3)      88 (13.7)      97 (24.7)     5 (14.7)       14 (7.3)      164 (11.7)         83 (36.6)
  Comorbidity (%)                                                                                                                                              
   AIDS/HIV                                          24 (1.5)      2 (0.6)        10 (1.6)       7 (1.8)       3 (8.8)        2 (1.0)       21 (1.5)           3 (1.3)
   Alcohol abuse                                     110 (6.7)     26 (7.2)       48 (7.5)       23 (5.9)      1 (2.9)        10 (5.2)      93 (6.6)           17 (7.5)
   Blood loss anemia                                 101 (6.2)     11 (3.0)       45 (7.0)       28 (7.1)      3 (8.8)        13 (6.8)      67 (4.8)           34 (15.0)
   Cardiac arrhythmias                               593 (36.3)    108 (29.8)     239 (37.1)     162 (41.3)    14 (41.2)      65 (33.9)     467 (33.2)         126 (55.5)
   Chronic pulmonary disease                         539 (33.0)    99 (27.3)      215 (33.4)     149 (38.0)    16 (47.1)      58 (30.2)     434 (30.9)         105 (46.3)
   Coagulopathy                                      188 (11.5)    30 (8.3)       74 (11.5)      53 (13.5)     2 (5.9)        28 (14.6)     135 (9.6)          53 (23.3)
   Congestive heart failure                          354 (21.7)    42 (11.6)      142 (22.0)     113 (28.8)    10 (29.4)      44 (22.9)     258 (18.3)         96 (42.3)
   Deficiency anemia                                 291 (17.8)    54 (14.9)      120 (18.6)     77 (19.6)     8 (23.5)       31 (16.1)     228 (16.2)         63 (27.8)
   Depression                                        446 (27.3)    76 (20.9)      181 (28.1)     137 (34.9)    12 (35.3)      39 (20.3)     360 (25.6)         86 (37.9)
   Diabetes, complicated                             440 (26.9)    67 (18.5)      178 (27.6)     115 (29.3)    17 (50.0)      60 (31.2)     349 (24.8)         91 (40.1)
   Diabetes, uncomplicated                           585 (35.8)    102 (28.1)     229 (35.6)     152 (38.8)    18 (52.9)      80 (41.7)     475 (33.8)         110 (48.5)
   Drug abuse                                        112 (6.9)     28 (7.7)       40 (6.2)       26 (6.6)      4 (11.8)       13 (6.8)      98 (7.0)           14 (6.2)
   Fluid and electrolyte disorders                   653 (40.0)    119 (32.8)     253 (39.3)     179 (45.7)    18 (52.9)      80 (41.7)     511 (36.3)         142 (62.6)
   Hypertension, complicated                         426 (26.1)    57 (15.7)      168 (26.1)     133 (33.9)    13 (38.2)      53 (27.6)     322 (22.9)         104 (45.8)
   Hypertension, uncomplicated                       1032 (63.2)   193 (53.2)     417 (64.8)     273 (69.6)    23 (67.6)      121 (63.0)    840 (59.7)         192 (84.6)
   Hypothyroidism                                    325 (19.9)    50 (13.8)      137 (21.3)     85 (21.7)     9 (26.5)       43 (22.4)     246 (17.5)         79 (34.8)
   Liver disease                                     219 (13.4)    47 (12.9)      81 (12.6)      56 (14.3)     6 (17.6)       27 (14.1)     175 (12.4)         44 (19.4)
   Lymphoma                                          24 (1.5)      5 (1.4)        8 (1.2)        9 (2.3)       0 (0)          2 (1.0)       19 (1.4)           5 (2.2)
   Metastatic cancer                                 112 (6.9)     19 (5.2)       45 (7.0)       34 (8.7)      3 (8.8)        9 (4.7)       88 (6.3)           24 (10.6)
   Obesity                                           508 (31.1)    97 (26.7)      200 (31.1)     128 (32.7)    15 (44.1)      64 (33.3)     438 (31.2)         70 (30.8)
   Other neurological disorders                      369 (22.6)    48 (13.2)      156 (24.2)     114 (29.1)    10 (29.4)      39 (20.3)     272 (19.3)         97 (42.7)
   Paralysis                                         78 (4.8)      6 (1.7)        34 (5.3)       24 (6.1)      3 (8.8)        11 (5.7)      62 (4.4)           16 (7.0)
   Peptic ulcer disease, excluding bleeding          87 (5.3)      18 (5.0)       32 (5.0)       28 (7.1)      1 (2.9)        8 (4.2)       66 (4.7)           21 (9.3)
   Peripheral vascular disorders                     370 (22.7)    53 (14.6)      140 (21.7)     117 (29.8)    10 (29.4)      47 (24.5)     278 (19.8)         92 (40.5)
   Psychoses                                         134 (8.2)     22 (6.1)       55 (8.5)       43 (11.0)     3 (8.8)        11 (5.7)      104 (7.4)          30 (13.2)
   Pulmonary circulation disorders                   157 (9.6)     27 (7.4)       48 (7.5)       51 (13.0)     5 (14.7)       23 (12.0)     110 (7.8)          47 (20.7)
   Renal failure                                     357 (21.9)    59 (16.3)      133 (20.7)     110 (28.1)    9 (26.5)       43 (22.4)     267 (19.0)         90 (39.6)
   Rheumatoid arthritis/collagen vascular diseases   127 (7.8)     18 (5.0)       57 (8.9)       31 (7.9)      5 (14.7)       15 (7.8)      101 (7.2)          26 (11.5)
   Solid tumor without metastasis                    230 (14.1)    35 (9.6)       93 (14.4)      65 (16.6)     8 (23.5)       27 (14.1)     179 (12.7)         51 (22.5)
   Valvular disease                                  377 (23.1)    53 (14.6)      169 (26.2)     107 (27.3)    6 (17.6)       38 (19.8)     290 (20.6)         87 (38.3)
   Weight loss                                       265 (16.2)    44 (12.1)      101 (15.7)     86 (21.9)     4 (11.8)       27 (14.1)     197 (14.0)         68 (30.0)

[^1]: These authors contributed equally to the work.
